Last reviewed · How we verify

NCT05295537: PEREUS

Percutaneous Versus Endoscopic Ultrasound-guided Liver Biopsy (PEREUS)

Completed NA Last updated 1 March 2023
What this trial tests

NA trial testing PERCUTANEOUS LIVER BIOPSY (PLB) in Liver Diseases in 92 participants. Completed in 1 December 2022.

Timeline
19 January 2022
Primary endpoint
1 September 2022
1 December 2022

Quick facts

Lead sponsorHospital Clinico Universitario de Santiago
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment92
Start date19 January 2022
Primary completion1 September 2022
Estimated completion1 December 2022
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Clinico Universitario de Santiago

Who can join

18 and older, any sex, with Liver Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although the use of liver biopsy (LB) has decreased with the emerging non-invasive markers and techniques to evaluate liver fibrosis, histopathologic examination of liver tissue is necessary to confirm the type of liver injury. The aim of our study is to compare two methods for obtaining histological material from the liver: the percutaneous liver biopsy (PLB) and the Endoscopic ultrasound (EUS) guided liver biopsy (EUS-LB)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Liver Diseases

Currently open trials in the same condition.

Other Hospital Clinico Universitario de Santiago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing